Esperion Therapeutics, Inc.
December 02, 2024 - by Joey Ramson
$ESPR is leading the Prism MarketView Public Health Index after the company said it has filed new submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk.
